BNT162b2 Reason 2 O O
mRNA Reason 2 O O
SARS-CoV-2 Reason 2 O O
Vaccine: Reason 2 O O
Low Reason 2 O O
Incidence Reason 2 O O
and Reason 2 O O
Mild Reason 2 O O
Severity. Reason 2 O O
Eur Reason 1 O O
Heart Reason 1 O O
J Reason 1 O O
2022;Jan Reason 1 O O
28:[Epub Reason 1 O O
ahead Reason 1 O O
of Reason 1 O O
print].](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab901/6516805) Reason 1 O O
The Reason 1 O O
following Reason 1 O O
are Reason 1 O O
key Reason 1 O O
points Reason 1 O O
to Reason 1 O O
remember Reason 1 O O
from Reason 1 O O
a Reason 1 O O
viewpoint Reason 1 O O
on Reason 1 O O
myocarditis Reason 1 O O
after Reason 1 O O
the Reason 1 O O
BNT162b2 Reason 1 O O
messenger Reason 1 O O
RNA Reason 1 O O
(mRNA) Reason 1 O O
severe Reason 1 O O
acute Reason 1 O O
respiratory Reason 1 O O
syndrome Reason 1 O O
coronavirus Reason 1 O O
2 Reason 1 O O
(SARS-CoV-2) Reason 1 O O
vaccine, Reason 1 O O
reporting Reason 1 O O
low Reason 1 O O
incidence Reason 1 O O
and Reason 1 O O
mild Reason 1 O O
severity: Reason 1 O O
- Reason 1 O O
The Reason 1 O O
risks Reason 1 O O
of Reason 1 O O
acute Reason 1 O O
myocarditis Reason 1 O O
associated Reason 1 O O
with Reason 1 O O
SARS-CoV-2 Reason 1 O O
mRNA Reason 1 O O
vaccination, Reason 1 O O
especially Reason 1 O O
in Reason 1 O O
male Reason 1 O O
teenagers, Reason 1 O O
have Reason 1 O O
raised Reason 1 O O
great Reason 1 O O
concern Reason 1 O O
and Reason 1 O O
garnered Reason 1 O O
intense Reason 1 O O
media Reason 1 O O
attention. Reason 1 O O
- Reason 1 O O
Myocarditis Reason 1 O O
in Reason 1 O O
general Reason 1 O O
practice, Reason 1 O O
independent Reason 1 O O
of Reason 1 O O
vaccination, Reason 1 O O
is Reason 1 O O
most Reason 1 O O
common Reason 1 O O
in Reason 1 O O
young Reason 1 O O
men Reason 1 O O
and Reason 1 O O
resolves Reason 1 O O
spontaneously Reason 1 O O
in Reason 1 O O
at Reason 1 O O
least Reason 1 O O
half Reason 1 O O
of Reason 1 O O
patients, Reason 1 O O
but Reason 1 O O
may Reason 1 O O
lead Reason 1 O O
to Reason 1 O O
dilated Reason 1 O O
cardiomyopathy, Reason 1 O O
heart Reason 1 O O
transplantation, Reason 1 O O
or Reason 1 O O
death Reason 1 O O
in Reason 1 O O
up Reason 1 O O
to Reason 1 O O
a Reason 1 O O
quarter Reason 1 O O
of Reason 1 O O
cases. Reason 1 O O
- Reason 1 O O
Historically, Reason 1 O O
myocarditis Reason 1 O O
has Reason 1 O O
been Reason 1 O O
reported Reason 1 O O
as Reason 1 O O
a Reason 1 O O
rare Reason 1 O O
adverse Reason 1 O O
event Reason 1 O O
after Reason 1 O O
vaccinations, Reason 1 O O
especially Reason 1 O O
smallpox, Reason 1 O O
influenza, Reason 1 O O
and Reason 1 O O
hepatitis Reason 1 O O
B Reason 1 O O
vaccinations Reason 1 O O
and Reason 1 O O
in Reason 1 O O
the Reason 1 O O
pre-coronavirus Reason 1 O O
disease Reason 1 O O
2019 Reason 1 O O
(COVID-19) Reason 1 O O
era. Reason 1 O O
Among Reason 2 O O
620,195 Reason 2 O O
reports Reason 2 O O
filed Reason 2 O O
at Reason 2 O O
the Reason 2 O O
United Reason 2 O O
States Reason 2 O O
Vaccine Reason 2 O O
Adverse Reason 2 O O
Event Reason 2 O O
Reporting Reason 2 O O
System Reason 2 O O
(VAERS) Reason 2 O O
between Reason 2 O O
1990 Reason 2 O O
and Reason 2 O O
2018, Reason 2 O O
0.1% Reason 2 O O
were Reason 2 O O
attributable Reason 2 O O
to Reason 2 O O
myopericarditis. Reason 2 O O
- Reason 1 O O
By Reason 1 O O
July Reason 1 O O
2021, Reason 1 O O
the Reason 1 O O
Centers Reason 1 ScientificAuthority O
for Reason 1 ScientificAuthority O
Disease Reason 1 ScientificAuthority O
Control Reason 1 ScientificAuthority O
and Reason 1 ScientificAuthority O
Prevention Reason 1 ScientificAuthority O
(CDC) Reason 1 ScientificAuthority O
reported Reason 1 O O
a Reason 1 O O
likely Reason 1 O O
association Reason 1 O O
between Reason 1 O O
the Reason 1 O O
SARS-CoV-2 Reason 1 O O
mRNA Reason 1 O O
vaccines Reason 1 O O
and Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
and Reason 1 O O
pericarditis; Reason 1 O O
the Reason 1 O O
reported Reason 1 O O
CDC Reason 1 ScientificAuthority O
myocarditis/pericarditis Reason 1 O O
rate Reason 1 O O
was Reason 1 O O
low, Reason 1 O O
approximately Reason 1 O O
12.6 Reason 1 O O
cases Reason 1 O O
per Reason 1 O O
million Reason 1 O O
second-dose Reason 1 O O
mRNA Reason 1 O O
vaccine Reason 1 O O
among Reason 1 O O
individuals Reason 1 O O
aged Reason 1 O O
12-39 Reason 1 O O
years. Reason 1 O O
- O O O O
Almost O O O O
all O O O O
confirmed O O O O
cases O O O O
of O O O O
acute O O O O
myocarditis O O O O
associated O O O O
with O O O O
COVID-19 O O O O
vaccination O O O O
with O O O O
follow-up O O O O
showed O O O O
resolution O O O O
of O O O O
symptoms; O O O O
and O O O O
among O O O O
those O O O O
who O O O O
had O O O O
follow-up O O O O
electrocardiogram/echocardiography O O O O
and O O O O
laboratory O O O O
testing, O O O O
most O O O O
had O O O O
returned O O O O
to O O O O
normal O O O O
status. O O O O
- Reason 4 O O
By Reason 4 O O
contrast, Reason 4 O O
the Reason 4 O O
incidence Reason 4 O O
of Reason 4 O O
COVID-19 Reason 4 O O
infection-associated Reason 4 O O
cardiac Reason 4 O O
injury Reason 4 O O
or Reason 4 O O
myocarditis Reason 4 O O
is Reason 4 O O
estimated Reason 4 O O
to Reason 4 O O
be Reason 4 O O
100 Reason 4 O O
times Reason 4 O O
higher Reason 4 O O
(1,000-1,400 Reason 4 O O
per Reason 4 O O
100,000 Reason 4 O O
people Reason 4 O O
with Reason 4 O O
COVID-19) Reason 4 O O
than Reason 4 O O
that Reason 4 O O
of Reason 4 O O
SARS-CoV-2 Reason 4 O O
mRNA-vaccine-related Reason 4 O O
myocarditis. Reason 4 O O
Moreover, Reason 4 O O
in Reason 4 O O
contrast Reason 4 O O
to Reason 4 O O
the Reason 4 O O
overall Reason 4 O O
mild Reason 4 O O
presentation Reason 4 O O
and Reason 4 O O
good Reason 4 O O
outcome Reason 4 O O
of Reason 4 O O
vaccine-associated Reason 4 O O
myocarditis, Reason 4 O O
COVID-19 Reason 4 O O
is Reason 4 O O
associated Reason 4 O O
with Reason 4 O O
a Reason 4 O O
higher Reason 4 O O
risk Reason 4 O O
of Reason 4 O O
cardiovascular Reason 4 O O
complications. Reason 4 O O
- Reason 1 O O
Two Reason 1 O O
recent Reason 1 O O
studies Reason 1 O O
reported Reason 1 O O
retrospective Reason 1 O O
data Reason 1 O O
on Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
presumed Reason 1 O O
myocarditis Reason 1 O O
that Reason 1 O O
were Reason 1 O O
detected Reason 1 O O
after Reason 1 O O
receipt Reason 1 O O
of Reason 1 O O
the Reason 1 O O
BNT162b2 Reason 1 O O
mRNA Reason 1 O O
vaccine Reason 1 O O
(Pfizer-BioNTech) Reason 1 O O
in Reason 1 O O
Israel. Reason 1 O O
Witberg Reason 1 O O
and Reason 1 O O
colleagues Reason 1 O O
identified Reason 1 O O
54 Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
among Reason 1 O O
>2.5 Reason 1 O O
million Reason 1 O O
vaccinated Reason 1 O O
persons Reason 1 O O
listed Reason 1 O O
in Reason 1 O O
the Reason 1 O O
database Reason 1 O O
of Reason 1 O O
health Reason 1 O O
care Reason 1 O O
organizations Reason 1 O O
with Reason 1 O O
an Reason 1 O O
overall Reason 1 O O
estimated Reason 1 O O
incidence Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
up Reason 1 O O
to Reason 1 O O
42 Reason 1 O O
days Reason 1 O O
after Reason 1 O O
at Reason 1 O O
least Reason 1 O O
one Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
vaccine Reason 1 O O
of Reason 1 O O
2.13 Reason 1 O O
cases Reason 1 O O
per Reason 1 O O
100,000 Reason 1 O O
persons Reason 1 O O
(95% Reason 1 O O
confidence Reason 1 O O
interval, Reason 1 O O
1.6-2.7). Reason 1 O O
- O O O O
Mevorach Reason 1 O O
et Reason 1 O O
al., Reason 1 O O
reported Reason 1 O O
136 Reason 1 O O
definite Reason 1 O O
or Reason 1 O O
probable Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
myocarditis Reason 1 O O
during Reason 1 O O
the Reason 1 O O
surveillance Reason 1 O O
of Reason 1 O O
approximately Reason 1 O O
5.1 Reason 1 O O
million Reason 1 O O
persons Reason 1 O O
receiving Reason 1 O O
two Reason 1 O O
doses Reason 1 O O
of Reason 1 O O
the Reason 1 O O
BNT162b2 Reason 1 O O
mRNA Reason 1 O O
vaccine, Reason 1 O O
with Reason 1 O O
an Reason 1 O O
incidence Reason 1 O O
of Reason 1 O O
0.6 Reason 1 O O
cases Reason 1 O O
per Reason 1 O O
100,000 Reason 1 O O
people Reason 1 O O
within Reason 1 O O
21 Reason 1 O O
days Reason 1 O O
after Reason 1 O O
the Reason 1 O O
first Reason 1 O O
dose Reason 1 O O
and Reason 1 O O
3.8 Reason 1 O O
cases Reason 1 O O
per Reason 1 O O
100,000 Reason 1 O O
people Reason 1 O O
within Reason 1 O O
21 Reason 1 O O
days Reason 1 O O
after Reason 1 O O
the Reason 1 O O
second Reason 1 O O
dose. Reason 1 O O
- Reason 1 O O
The Reason 1 O O
mechanism Reason 1 O O
of Reason 1 O O
acute Reason 1 O O
myocarditis Reason 1 O O
associated Reason 1 O O
with Reason 1 O O
COVID-19 Reason 1 O O
vaccination Reason 1 O O
is Reason 1 O O
not Reason 1 O O
known Reason 1 O O
but Reason 1 O O
may Reason 1 O O
be Reason 1 O O
related Reason 1 O O
to Reason 1 O O
mRNA Reason 1 O O
sequence Reason 1 O O
that Reason 1 O O
encodes Reason 1 O O
for Reason 1 O O
the Reason 1 O O
spike Reason 1 O O
protein Reason 1 O O
of Reason 1 O O
SARS-CoV-2, Reason 1 O O
or Reason 1 O O
to Reason 1 O O
the Reason 1 O O
immune Reason 1 O O
response Reason 1 O O
that Reason 1 O O
follows Reason 1 O O
vaccination. Reason 1 O O
The Reason 1 O O
propensity Reason 1 O O
of Reason 1 O O
young Reason 1 O O
adults Reason 1 O O
to Reason 1 O O
develop Reason 1 O O
myocarditis Reason 1 O O
following Reason 1 O O
the Reason 1 O O
second Reason 1 O O
dose Reason 1 O O
of Reason 1 O O
vaccine Reason 1 O O
supports Reason 1 O O
the Reason 1 O O
hypothesis Reason 1 O O
of Reason 1 O O
the Reason 1 O O
vaccine-associated Reason 1 O O
maladaptive Reason 1 O O
immune Reason 1 O O
response, Reason 1 O O
related Reason 1 O O
to Reason 1 O O
sex Reason 1 O O
hormone Reason 1 O O
differences, Reason 1 O O
causing Reason 1 O O
cardiac Reason 1 O O
injury. Reason 1 O O
- Reason 3 O O
Available Reason 3 O O
data Reason 3 O O
suggest Reason 3 O O
that Reason 3 O O
the Reason 3 O O
risk Reason 3 O O
of Reason 3 O O
acute Reason 3 O O
myocarditis Reason 3 O O
associated Reason 3 O O
with Reason 3 O O
COVID-19 Reason 3 O O
vaccination Reason 3 O O
is Reason 3 O O
very Reason 3 O O
low, Reason 3 O O
although Reason 3 O O
more Reason 3 O O
common Reason 3 O O
in Reason 3 O O
young Reason 3 O O
male Reason 3 O O
patients. Reason 3 O O
Furthermore, O O O O
vaccine-related O O O O
myocarditis O O O O
is O O O O
self-limiting O O O O
in O O O O
most O O O O
cases. O O O O
These Reason 5 O O
data Reason 5 O O
should Reason 5 O O
reassure Reason 5 O O
physicians, Reason 5 O O
patients, Reason 5 O O
the Reason 5 O O
general Reason 5 O O
population, Reason 5 O O
and Reason 5 O O
media, Reason 5 O O
as Reason 5 O O
the Reason 5 O O
benefit-risk Reason 5 O O
assessment Reason 5 O O
for Reason 5 O O
SARS-CoV-2 Reason 5 O O
mRNA Reason 5 O O
vaccination Reason 5 O O
shows Reason 5 O O
a Reason 5 O O
highly Reason 5 O O
favorable Reason 5 O O
balance Reason 5 O O
for Reason 5 O O
vaccination Reason 5 O O
across Reason 5 O O
all Reason 5 O O
age Reason 5 O O
and Reason 5 O O
sex Reason 5 O O
groups. Reason 5 O O
Clinical O O O O
Topics: O O O O
[Cardiac O O O O
Surgery, O O O O
](/Clinical-Topics/Cardiac-Surgery) O O O O
[Cardiovascular O O O O
Care O O O O
Pediatrics, O O O O
](/Clinical-Topics/Cardiac-Surgery/Cardiac-Surgery-and-CHD-Pediatrics) O O O O
[Cardiac O O O O
Surgery O O O O
and O O O O
Heart O O O O
Failure, O O O O
](/Clinical-Topics/Cardiac-Surgery/Cardiac-Surgery-and-Heart-Failure) O O O O
[CHD O O O O
and O O O O
Pediatrics O O O O
Arrhythmias, O O O O
](/Clinical-Topics/Congenital-Heart-Disease-Pediatric-Cardiology/CHD-Pediatrics-and-Arrhythmias) O O O O
[CHD O O O O
and O O O O
Pediatrics O O O O
Imaging, O O O O
](/Clinical-Topics/Congenital-Heart-Disease-Pediatric-Cardiology/CHD-Pediatrics-and-Imaging) O O O O
[CHD O O O O
and O O O O
Pediatrics O O O O
and O O O O
Interventions, O O O O
](/Clinical-Topics/Congenital-Heart-Disease-Pediatric-Cardiology/CHD-Pediatrics-and-Interventions) O O O O
[CHD O O O O
and O O O O
Pediatrics O O O O
and O O O O
Prevention, O O O O
](/Clinical-Topics/Congenital-Heart-Disease-Pediatric-Cardiology/CHD-Pediatrics-and-Prevention) O O O O
[CHD O O O O
and O O O O
Pediatrics O O O O
and O O O O
Quality O O O O
Improvement, O O O O
](/Clinical-Topics/Congenital-Heart-Disease-Pediatric-Cardiology/CHD-Pediatrics-and-Quality-Improvement) O O O O
[Acute O O O O
Adverse O O O O
Drug O O O O
Reporting O O O O
Systems, O O O O
Cardiomyopathy, O O O O
Dilated, O O O O
COVID-19, O O O O
COVID-19 O O O O
Vaccines, O O O O
Echocardiography, O O O O
Electrocardiography, O O O O
Heart O O O O
Failure, O O O O
Heart O O O O
Transplantation, O O O O
Immunity, O O O O
Mass O O O O
Vaccination, O O O O
Myocarditis, O O O O
Pericarditis, O O O O
Primary O O O O
Prevention, O O O O
Risk O O O O
Assessment, O O O O
RNA, O O O O
Messenger, O O O O
SARS-CoV-2, O O O O
Spike O O O O
